Regen 24-Hour Summary
Orthopaedic and Rehabilitation Devices Panel Meeting – March 23, 2010
The Orthopaedic and Rehabilitation Devices Panel met on March 23, 2010, to discuss and make recommendations on scientific issues relevant to FDA’s reevaluation of the ReGen Collagen Scaffold (CS) device (marketed as the Menaflex®), which FDA cleared in K082079 on December 18, 2008, sponsored by ReGen Biologics, Inc. The panel gave scientific and clinical input on the data that was submitted in the 510(k). The Panel deliberated on the safety and effectiveness of this product as evidenced from data provided from the submitted studies.
The sponsor and FDA presentations focused on the scientific issues related to the 510(k) review process including the clinical data collected on the subject device. The clinical data were collected in a multi-center study intended to assess the safety and effectiveness of the ReGen Collage Scaffold (CS) device. The sponsor claimed substantial equivalence to 3 main predicate devices with approximately 26 predicate devices mentioned in their submission. The FDA posed questions to the advisory panel that were aimed at identifying whether or not the indications were a new intended use altering the therapeutic effect and whether or not the technology of the ReGen device raised new types of safety and effectiveness questions compared to the sponsor’s chosen predicate devices.
The Panel discussion in the afternoon session addressed key issues/questions posed by FDA. The Panel discussed and decided that there was insufficient evidence that the device, at time zero, reinforces and repairs soft tissue injuries. The panel decided that the tissues that ultimately grow in place of the device, as it degrades, may serve to partially reinforce and repair in the long-term, but not fully and that the definition of repair and replace should be further defined. The panel stated that the device is a scaffold that fills a void that reconstructs the removed tissue. The Panel also decided that the anatomic design and comparisons to other products is generally considered safe, but they had concerns about the overall effectiveness. Moreover, the panel determined that the difference in the anatomical design may contain a reasonable amount of stress that has not been adequately assessed. There was a lengthy discussion about tensile strength over time. The Panel did form a consensus that due to the low number of device failures, the device can be viewed as reasonably safe, but the device’s effectiveness would need to be analyzed further. In order to determine effectiveness, the panel stated that follow-ups on participants, further imaging studies and predetermined endpoints would need to be analyzed.
Contact: Tracy Phillips, Ph.D., Designated Federal Officer at 301‐796‐6150 Tracy.Phillips@fda.hhs.gov
Transcripts may be purchased from: (written requests only) Free State Reporting, Inc. 1378 Cape St. Claire Road Annapolis, MD 21409 410‐974‐0947 or 800‐231‐8973 Ext. 103 410‐974‐0297 fax
Food and Drug Administration Freedom of Information Staff (FOI) 5600 Fishers Lane, HFI‐35 Rockville, MD 20851 (301) 827‐6500 (voice), (301) 443‐1726 (fax)